International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Comparative analysis of Homo sapiens ERBB2 erb-b2 receptor tyrosine kinase 2

    , ,

Author Affiliations

  • 1Lahore Garrison University, Lahore Pakistan
  • 2District Head Quarter Hospital (DHQ), Faisalabad, Pakistan
  • 3Lahore Garrison University, Lahore Pakistan

Int. Res. J. Biological Sci., Volume 6, Issue (6), Pages 1-6, June,10 (2017)

Abstract

Growth factors are special proteins which help to stimulate proliferation and differentiation in both normal and malignant cells. The first growth factor was epidermal growth factor. The receptor tyrosine kinases includes the receptor epidermal growth factor receptor EFGR. They have many other members like erbB2/HER-2, erbB3/HER-3, and erbB4/HER. These receptors are anchored in the cytoplasmic membrane and share a similar structure that is composed of an extracellular ligand-binding domain, a short hydrophobic transmembrane region, and an intracytoplasmic tyrosine kinase domain. Activation of these receptor leads to the phosphorylation of important tyrosine residues within the COOH-terminal portion of EGFR resulting in specific docking sites for cytoplasmic proteins. To overcome various problems associated with ERBB gene mutations, prior identification and analysis of these mutations is necessary. In this study, we have analyzed the ERBB receptor tyrosine kinase, its structural classification and various protein domains by using bioinformatics tools.

References

  1. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J. and Yokoyama S. (2003)., An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors., Molecular cell, 12(3), 541-552.
  2. Hubbard S.R. (2005)., EGF receptor inhibition: attacks on multiple fronts., Cancer cell, 7(4), 287-288.
  3. Frederick L., Wang X.Y., Eley G. and James C.D. (2000)., Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas., Cancer research, 60(5), 1383-1387.
  4. Anido J., Scaltriti M., Serra J.J.B., Josefat B.S., Todo F.R., Baselga J. and Arribas J. (2006)., Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation., The EMBO journal, 25(13), 3234-3244.
  5. Liu D., Ghiso J.A.A., Estrada Y. and Ossowski L. (2002)., EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma., Cancer cell, 1(5), 445-457.
  6. Fischer O.M., Hart S., Gschwind A. and Ullrich A. (2003)., EGFR signal transactivation in cancer cells., Biochemical Society Transactions, 31(6), 1203-1208.
  7. Tan M., Li P., Klos K.S., Lu J., Lan K.H., Nagata Y. and Yu D. (2005)., ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis., Cancer research, 65(5), 1858-1867.
  8. Tan M., Lan K.H., Yao J., Lu C.H., Sun M., Neal C.L. and Yu D. (2006)., Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3–blocking peptide., Cancer research, 66(7), 3764-3772.
  9. Sun M., Li P., Tan M. and Yin G. (2006)., Upregulation and activation of PKCż by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCż and Src inhibitors., Oncogene: An International Journal, 25(23), 3286-3295.
  10. Yarden Y. and Sliwkowski M.X. (2001)., Untangling the ErbBsignalling network., Nature reviews Molecular cell biology, 2(2), 127-137.
  11. Zhou X., Tan M., Hawthorne V.S., Klos K.S., Lan K.H., Yang Y. and Yu D. (2004)., Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers., Clinical Cancer Research, 10(20), 6779-6788.
  12. Zhang H., Berezov A., Wang Q., Zhang G., Drebin J., Murali R. and Greene M.I. (2007)., ErbB receptors: from oncogenes to targeted cancer therapies., The Journal of clinical investigation, 117(8), 2051-2058.
  13. Giaccone G. and Rodriguez J.A. (2005)., EGFR inhibitors: what have we learned from the treatment of lung cancer?., Nature Clinical Practice Oncology, 2(11), 554-561.
  14. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L. and Ludovini V. (2005)., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer., Journal of the National Cancer Institute, 97(9), 643-655.
  15. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M. and Varmus H.E. (2005)., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib., PLoS medicine, 2(1), e17.
  16. Olayioye M.A. (2001)., Intracellular signaling pathways of ErbB2/HER-2 and family members., Breast Cancer Research, 3(6), 385.
  17. Cho H.S. and Leahy D.J. (2002)., Structure of the extracellular region of HER3 reveals an interdomain tether., Science, 297(5585), 1330-1333.
  18. Bublil E.M. and Yarden Y. (2007)., The EGF receptor family: spearheading a merger of signaling and therapeutics., Current opinion in cell biology, 19(2), 124-134.
  19. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D. and Muller W.J. (1992)., Expression of the neuprotooncogene in the mammary epithelium of transgenic mice induces metastatic disease., Proceedings of the National Academy of Sciences, 89(22), 10578-10582.
  20. Stern D.F. (2000)., Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases., Breast Cancer Research, 2(3), 176.
  21. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J. and Yokoyama S. (2003)., An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors., Molecular cell, 12(3), 541-552.
  22. Hubbard S.R. (2005)., EGF receptor inhibition: attacks on multiple fronts., Cancer cell, 7(4), 287-288.
  23. Frederick L., Wang X.Y., Eley G. and James C.D. (2000)., Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas., Cancer research, 60(5), 1383-1387.
  24. Anido J., Scaltriti M., Serra J.J.B., Josefat B.S., Todo F.R., Baselga J. and Arribas J. (2006)., Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation., The EMBO journal, 25(13), 3234-3244.
  25. Liu D., Ghiso J.A.A., Estrada Y. and Ossowski L. (2002)., EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma., Cancer cell, 1(5), 445-457.
  26. Fischer O.M., Hart S., Gschwind A. and Ullrich A. (2003)., EGFR signal transactivation in cancer cells., Biochemical Society Transactions, 31(6), 1203-1208.
  27. Tan M., Li P., Klos K.S., Lu J., Lan K.H., Nagata Y. and Yu D. (2005)., ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis., Cancer research, 65(5), 1858-1867.
  28. Tan M., Lan K.H., Yao J., Lu C.H., Sun M., Neal C.L. and Yu D. (2006)., Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3–blocking peptide., Cancer research, 66(7), 3764-3772.
  29. Sun M., Li P., Tan M. and Yin G. (2006)., Upregulation and activation of PKCż by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCż and Src inhibitors., Oncogene: An International Journal, 25(23), 3286-3295.
  30. Yarden Y. and Sliwkowski M.X. (2001)., Untangling the ErbBsignalling network., Nature reviews Molecular cell biology, 2(2), 127-137.
  31. Zhou X., Tan M., Hawthorne V.S., Klos K.S., Lan K.H., Yang Y. and Yu D. (2004)., Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers., Clinical Cancer Research, 10(20), 6779-6788.
  32. Zhang H., Berezov A., Wang Q., Zhang G., Drebin J., Murali R. and Greene M.I. (2007)., ErbB receptors: from oncogenes to targeted cancer therapies., The Journal of clinical investigation, 117(8), 2051-2058.
  33. Giaccone G. and Rodriguez J.A. (2005)., EGFR inhibitors: what have we learned from the treatment of lung cancer?., Nature Clinical Practice Oncology, 2(11), 554-561.
  34. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L. and Ludovini V. (2005)., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer., Journal of the National Cancer Institute, 97(9), 643-655.
  35. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M. and Varmus H.E. (2005)., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib., PLoS medicine, 2(1), e17.
  36. Olayioye M.A. (2001)., Intracellular signaling pathways of ErbB2/HER-2 and family members., Breast Cancer Research, 3(6), 385.
  37. Cho H.S. and Leahy D.J. (2002)., Structure of the extracellular region of HER3 reveals an interdomain tether., Science, 297(5585), 1330-1333.
  38. Bublil E.M. and Yarden Y. (2007)., The EGF receptor family: spearheading a merger of signaling and therapeutics., Current opinion in cell biology, 19(2), 124-134.
  39. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D. and Muller W.J. (1992)., Expression of the neuprotooncogene in the mammary epithelium of transgenic mice induces metastatic disease., Proceedings of the National Academy of Sciences, 89(22), 10578-10582.
  40. Stern D.F. (2000)., Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases., Breast Cancer Research, 2(3), 176.